By Cheche V. Moral Philippine Daily Inquirer DR.MARK Berman of the California Stem Cell Treatment Center, Dr. LeoOlarte of the Philippine Medical Association, Dr. Aivee Aguilar-Teo and Dr. Z Teo of StemCare Institute Center for Pain and Regenerative Medicine The Department of Health and some medical organizations are calling for a clampdown on hospitals, clinics and centers offering stem cell treatments. But instead of being discouraged, one of stem cell therapys vocal advocates and practitioners in the country said she welcomes the move. At the launch of StemCare Institute Center for Pain and Regenerative Medicine, a new division of The Skin and Laser Clinic, Dr. Aivee Aguilar-Teo said she believes the procedure needs to be regulated. The word stem cell has been used loosely, which is sad. So [the crackdown] is good in a way because we really need to regulate, said Dr. Aguilar-Teo, who, with her Singaporean physician husband, Z, owns and runs StemCare. Theres this impression that all stem cell treatments are the same, which isnt the case. The techniques and sources of stem cells are different [from clinic to clinic]. The Teos clinic at Bonifacio Global City has been offering autologous fat stem cell repair (FSCR) for … Continue reading →

BERLIN--(Marketwired - Aug 29, 2013) - MagForce AG / Voluntary Directors' Dealings announcement of Dr. Ben J. Lipps . Ad hoc announcement according to 15 WpHG. Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement. MagForce AG (Frankfurt, Entry Standard, XETRA: MF6), a leading medical device company in the field of nanomedicine focused on oncology, announced today that Ben Lipps, designated CEO starting September 1st, 2013, has disclosed to the Company that he has bought 250,000 shares in MagForce, which represents 1.05% of the Company's outstanding shares. About MagForce AG MagForce AG is a leading medical device company in the field of nanomedicine in oncology, listed in the entry standard (MF6). The Company's proprietary, NanoTherm therapy, enables the targeted treatment of solid tumors through the intratumoral generation of heat via activation of superparamagnetic nanoparticles. NanoTherm, NanoPlan, and NanoActivator are components of the therapy and have received EU-wide regulatory approval as medical devices for the treatment of brain tumors. MagForce, NanoTherm, NanoPlan, and NanoActivator are trademarks of MagForce AG in selected countries. For more information, please visit http://www.magforce.com. Disclaimer This release may contain forward-looking statements and information which may be identified by … Continue reading →

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- BIND Therapeutics, a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called AccurinsTM, announced today that it has been recognized by the World Economic Forum as a Technology Pioneer 2014. The Technology Pioneers 2014 will be honored at the Forums Annual Meeting of the New Champions 2013 in Dalian, Peoples Republic of China, from 11 to 13 September. Each year the World Economic Forum chooses a select number of Technology Pioneers from hundreds of applicants. Candidate companies are nominated by Members, constituents and collaborators of the World Economic Forum, and by the public. A selection committee, comprised of top technology and innovation experts, academics and venture capitalists, reviews all applications before making its recommendation to the World Economic Forum. More information about the World Economic Forums Technology Pioneers program can be found at http://www.weforum.org/techpioneers. About BIND Therapeutics BIND Therapeutics is a clinical-stage nanomedicine platform company developing Accurins, its novel targeted therapeutics. BIND intends to leverage its medicinal nanoengineering platform to develop a pipeline of Accurins, initially in oncology, as well as Accurins in collaboration with biopharmaceutical companies. BINDs lead drug candidate, BIND-014, is an Accurin that targets PSMA and contains docetaxel, a clinically-validated and widely used … Continue reading →

Berlin, Germany, August 29, 2013 - MagForce AG (Frankfurt, Entry Standard, XETRA: MF6), a leading medical device company in the field of nanomedicine focused on oncology, announced today that Ben Lipps, designated CEO starting September 1st, 2013, has disclosed to the Company that he has bought 250,000 shares in MagForce, which represents 1.05% of the Company`s outstanding shares. About MagForce AG MagForce AG is a leading medical device company in the field of nanomedicine in oncology, listed in the entry standard (MF6). The Company`s proprietary, NanoTherm therapy, enables the targeted treatment of solid tumors through the intratumoral generation of heat via activation of superparamagnetic nanoparticles. NanoTherm, NanoPlan, and NanoActivator(TM) are components of the therapy and have received EU-wide regulatory approval as medical devices for the treatment of brain tumors. MagForce, NanoTherm, NanoPlan, and NanoActivator(TM) are trademarks of MagForce AG in selected countries. For more information, please visit http://www.magforce.com. Disclaimer This release may contain forward-looking statements and information which may be identified by formulations using terms such as "expects", "aims", "anticipates", "intends", "plans", "believes", "seeks", "estimates" or "will". Such forward-looking statements are based on our current expectations and certain assumptions, which may be subject to a variety of risks and uncertainties. … Continue reading →

PARIS--(Marketwired - Aug 30, 2013) - NANOBIOTIX (the "Company") (EURONEXT PARIS: NANO), a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, has published today its half year results for the six month period ended 30 June 2013 (HY1). Half year highlights include: Financial highlights: Main operational highlights: Post period end main highlights: Laurent Levy, Chief Executive Officer at Nanobiotix, said: "We have made excellent clinical progress in the period, beyond what we originally expected, and we would like to accelerate this further if possible. The second half of the year started well and we expect the initiation of the new clinical trial and the reporting of trial results in the period. We continue to control costs tightly and have focused on strengthening the Company's structure and governance during the period. We have also received a grant from the Bpifrance which not only acknowledges the potential impact of our technology in cancer treatment, but also is helpful in managing the cash flow. Our strategy is to seek further international collaborations that will allow us to provide sustainable company growth, but we also want to drive progress forward ourselves, with the continued support of our shareholders. As part … Continue reading →

Dr. Mayo Friedlis - When Should You Use Stem Cell Therapy? Dr. Mayo Friedlis of Stemcell ARTS (an affiliate of National Spine and Pain Centers) in Fairfax, Virginia introduces stem cell therapy, an innovative solution that can deliver non-surgical... By: StemCell ARTS … Continue reading →

The bad news: "Stem cells by themselves do not work." The good news: "Stem cells by themselves do not work." Take it from the doctor who has treated 5,000 patients with stem cell therapy, a doctor who is himself a cancer survivor. Thirteen years ago, Dr. Sam Bernal - oncologist, chemist, molecular biologist, lawyer, professor and lecturer, among other things - was a cancer patient who thought he was at death's door. Using stem cells sourced from his bone marrow and peripheral blood, he overcame the disease and has since become an advocate of living fit, living well in order to look good. Dr. Bernal, who divides his time between Los Angeles, Prague, Makati, and Germany, was a pioneer in stem cell research in the Philippines early on in his career, for which he was cited when he received the Presidential Award for Outstanding Filipinos Overseas from President Benigno S, Aquino III in 2012. At a recent meeting with journalists, Dr. Bernal hurled the challenge: "What do you need stem cell therapy for if you eat well, sleep soundly, exercise regularly, don't smoke, have a positive attitude, and know how to live in the moment as you gaze at a … Continue reading →

Right off the bat, Dr. Ed Santos, oncologist and surgeon who trained in stem cell therapy in Belgium and has been a medical doctor for 30 years, will tell you how old he is. "I'm 60." Well can he afford to brag, because his skin is clear, rosy and bright, while the rest of him shows a body that is just about to ripen for middle age. In his brand-new StemGenics Center for Age Management and Regenerative Medicine on Eisenhower St. in Greenhills, San Juan, the doctor proudly gives the visitor a tour of the clinic's gleaming equipment and facilities, all because its principal investor, Sunder Hemandas, believes that "SCT is the future of medicine." There's another reason for the pride in the doctor's voice. Unlike some fly-by-night "clinics" operating out of hotel rooms, StemGenics is endorsed by the Department of Health. The following are excerpts of a conversation with Dr. Santos. When does someone need stem cell therapy? There is an increasing demand for the use of stem cells as therapy in oncology, end-organ diseases and regenerative medicine, as well as aesthetic applications. Despite the heightened interest, SCT is not a cure-all treatment. It should be considered when standard … Continue reading →

Thursday, August 22, 2013 PHOENIX Mayo Clinic in Arizona, with one of the most active bone marrow transplant programs in United States, will open its own stem cell laboratory in summer 2014. The laboratory will be initially dedicated to storing and processing stem cells used for bone marrow transplants at Mayo Clinic Hospital and Phoenix Children's Hospital. Mayo Clinic is a regional referral center and performs more than 200 adult stem cell transplants each year and approximately 30 pediatric transplants with Phoenix Children's. The program is accredited by the Foundation for the Accreditation of Cellular Therapy and the National Bone Marrow Donor Program. Stem cell (blood or marrow) transplant is the infusion or injection of healthy stem cells into the body to replace damaged or diseased stem cells. Although the procedure to replenish the body's supply of healthy blood-forming cells is generally called a stem cell transplant, it's also known as a bone marrow transplant, peripheral blood stem cell transplant or an umbilical cord blood transplant, depending on the source of the stem cells. Stem cell transplants can use cells from a person's own body (autologous stem cell transplant), from a donor (allogeneic stem cell transplant) or from an identical … Continue reading →

Released: 8/22/2013 7:00 PM EDT Source Newsroom: Mayo Clinic Newswise PHOENIX Mayo Clinic in Arizona, with one of the most active bone marrow transplant programs in United States, will open its own stem cell laboratory in summer 2014. The laboratory will be initially dedicated to storing and processing stem cells used for bone marrow transplants at Mayo Clinic Hospital and Phoenix Childrens Hospital. Mayo Clinic is a regional referral center and performs more than 200 adult stem cell transplants each year and approximately 30 pediatric transplants with Phoenix Childrens. The program is accredited by the Foundation for the Accreditation of Cellular Therapy and the National Bone Marrow Donor Program. Stem cell (blood or marrow) transplant is the infusion or injection of healthy stem cells into the body to replace damaged or diseased stem cells. Although the procedure to replenish the body's supply of healthy blood-forming cells is generally called a stem cell transplant, it's also known as a bone marrow transplant, peripheral blood stem cell transplant or an umbilical cord blood transplant, depending on the source of the stem cells. Stem cell transplants can use cells from a persons own body (autologous stem cell transplant), from a donor (allogeneic stem … Continue reading →